Somatostatin Analogues as a Therapeutic Option in a Series of 91 Patients with Gastric Carcinoids

#184

Introduction: Gastric carcinoid tumors (GC) represent about 10-30% of carcinoid tumors and about 1% of all stomach neoplasms. They include three types : type 1 (70-85%), type 2 (5-10%) and type 3 (15-25%).

Aim(s): To evaluate the diagnostic approach and the significance of somatostatin analogues (SSA's) as a therapeutic option for patients (pts) with GC.

Materials and methods: Twenty-three males and 58 females with GC (mean age at diagnosis 60.5 years) refered to our Section of GI Neuroendocrinology over the last 20 years. Follow-up period ranged from 24 to 108 months. They were evaluated for serum gastrin and CgA levels and with gastroscopy every six months, before, during and after the treatment with SSA's.

Conference: 8th Annual ENETSConcerence (2011)

Presenting Author:

Authors: Basagiannis C, Angelopoulos T, Papadimitriou C, Geragotou T, Siakavellas S,

Keywords: gastric carcinoid, gastrin, Somatostatin analogues.,